1910genetics

1910genetics is a pioneering biotechnology company at the forefront of transforming the pharmaceutical industry. It addresses the fundamental flaws in the traditional research and development (R&D) model, which is notoriously slow (12-15 years), expensive (averaging $2.5 billion per drug), and inefficient (with a failure rate exceeding 90%). The company's vision is to make previously "undruggable" targets a thing of the past by building the essential infrastructure layer for tech-enabled drug discovery. At its core is a multimodal AI platform, ITO™, powered by advanced laboratory automation and designed to accelerate the discovery of both small and large molecule therapeutics. By integrating artificial intelligence with three proprietary data streams, 1910genetics aims to significantly shorten development cycles, reduce costs, and increase the probability of clinical success for new treatments targeting neurological diseases, autoimmune disorders, and cancer.

How to use 1910genetics

As an enterprise-level platform, 1910genetics is not a self-service software but a powerful engine for collaboration with pharmaceutical and biotechnology partners. Engagement is facilitated through several flexible partnership models designed to meet diverse R&D needs:

• Co-Discovery: In this model, partners define the target and desired drug-like properties. 1910genetics then leverages its end-to-end ITO™ platform to design, manufacture, test, and deliver a novel small or large molecule drug candidate that meets these pre-specified criteria.
• Co-Engineering: This collaborative approach allows partners to work directly with the 1910genetics team. The collaboration focuses on engineering bespoke discovery modules by integrating partner data, AI models, and computational resources. The outcome is a tailored solution that can be integrated into the partner's internal R&D workflows.
• Platform-as-a-Service (PaaS): (Coming Soon) This future offering will provide partners with direct software access to specific modules within the ITO™ platform, enabling them to run their own discovery processes on the powerful infrastructure built by 1910genetics.
• Asset Licensing: 1910genetics actively develops its own internal pipeline of therapeutics. Lead compounds discovered through this internal research are made available for licensing to strategic partners who can then take them through further clinical development and commercialization.

Core Features of 1910genetics

The power of 1910genetics lies in its proprietary Input-Transform-Output (ITO™) platform, a comprehensive, modality-agnostic system.

• Multimodal AI Platform (ITO™): An end-to-end system that integrates data generation, AI-driven design, and automated lab validation in a closed loop, covering the entire discovery pipeline from target identification to in vivo testing.
• Three Proprietary Data Streams: The platform is fueled by a unique combination of data: 1. Computational Data (billions of data points from simulations), 2. Wet Lab Proxy Biological Data (from high-throughput surrogate assays), and 3. Wet Lab Ground Truth Biological Data (from robotics-driven lab automation).
• Advanced AI and Computational Methods: The platform deploys a diverse range of state-of-the-art model architectures, including Large Language Models (LLMs), diffusion models, and attentive graph neural networks, alongside computational methods like molecular dynamics and quantum mechanics.
• Modality Agnostic Discovery: The platform is versatile, capable of designing both small molecules (e.g., covalent inhibitors, protein degraders) and large molecules (e.g., peptides, monoclonal antibodies, ADCs).
• Predictive Drug-Likeness (ADMET): Integrated AI models predict key drug properties—Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET)—to filter and prioritize candidates with a higher chance of clinical success.
• Synthesis and Manufacturability Optimization: The platform optimizes for high synthetic yield, ensuring that the designed molecules are not just effective but also manufacturable at scale.

Use Cases for 1910genetics

The ITO™ platform is applicable across a wide range of therapeutic areas and R&D challenges.

• Accelerating Preclinical Development: Pharmaceutical companies can partner with 1910genetics to drastically shorten the timeline for identifying and optimizing lead compounds, moving from years to months.
• Targeting "Undruggable" Proteins: For complex diseases driven by proteins that have resisted traditional drug discovery methods, 1910genetics' AI can explore vast chemical spaces to design novel molecules that can effectively modulate these targets.
• Developing Novel Therapeutics: The platform is actively used to advance pipelines in high-need areas, including precision oncology, neuroscience (e.g., predicting blood-brain barrier permeability with CANDID-CNS™), autoimmune diseases, and rare genetic disorders.
• De-risking Drug Candidates: By using predictive modeling and extensive validation early in the process, the platform helps eliminate unpromising candidates sooner, focusing resources on those with the highest potential.

Advantages of 1910genetics

• End-to-End Integration: Unlike point solutions that only address one part of the discovery process, 1910genetics provides a fully integrated platform from initial concept to validated candidate.
• Superior Data Foundation: The unique combination of computational, proxy, and ground-truth wet lab data creates a powerful flywheel effect, where each cycle of design and validation improves the AI models.
• Speed and Cost-Effectiveness: The platform is designed to fundamentally change the economics of drug discovery, aiming to deliver better therapies to patients faster and at a lower cost.
• Strategic Industry Partnerships: Collaborations with tech giants like Microsoft and consulting leaders like Accenture amplify the platform's capabilities and reach.

Pricing and Plans

1910genetics operates on a partnership-based business model. Pricing is not standardized and is tailored to the specific needs and scope of each collaboration. Interested parties are encouraged to contact the company directly to discuss one of their flexible engagement models: Co-Discovery, Co-Engineering, Asset Licensing, or to join the waiting list for the upcoming Platform-as-a-Service (PaaS) offering.